Genetic Analysis Investor Relations Material
Latest events
Status Update
Genetic Analysis
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Genetic Analysis
Access all reports
Segment Data
Access more data
Revenue by
Geography
U.S.
Europe
RoW
Expenses by
Financials
Genetic Analysis AS's mission is to develop, document, clinically validate and commercialize in vitro diagnostic tests for diagnosis and characterizing of dysbiosis in Irritable Bowel Syndrome and Inflammatory Bowel Disease patients. Genetic Analysis AS will initially focus on new ways to help diagnose IBS-D. The company has developed a non-invasive laboratory test for microbiology that can help to confirm the presence of diarrheal IBS. The intent is to provide improved disease characterization for physicians treating large numbers of dysbiosis patients with IBS or IBD with the goal of helping the physician in the management of these patients.
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇳🇴 Norway